PL195031B1 - Ciekła wodna kompozycja nadająca się do nalewaniazawierająca alginian i wodorowęglan metalu alkalicznego - Google Patents
Ciekła wodna kompozycja nadająca się do nalewaniazawierająca alginian i wodorowęglan metalu alkalicznegoInfo
- Publication number
- PL195031B1 PL195031B1 PL98336724A PL33672498A PL195031B1 PL 195031 B1 PL195031 B1 PL 195031B1 PL 98336724 A PL98336724 A PL 98336724A PL 33672498 A PL33672498 A PL 33672498A PL 195031 B1 PL195031 B1 PL 195031B1
- Authority
- PL
- Poland
- Prior art keywords
- alginate
- sodium alginate
- compositions
- mannuronic
- acid residue
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 76
- 235000010413 sodium alginate Nutrition 0.000 title claims description 34
- 239000000661 sodium alginate Substances 0.000 title claims description 29
- 229940005550 sodium alginate Drugs 0.000 title claims description 29
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 title claims description 27
- 239000007788 liquid Substances 0.000 title claims description 10
- -1 alkali metal bicarbonate Chemical class 0.000 title claims description 9
- 229910052783 alkali metal Inorganic materials 0.000 title claims description 8
- 125000005613 guluronic acid group Chemical group 0.000 claims abstract description 22
- AEMOLEFTQBMNLQ-VANFPWTGSA-N D-mannopyranuronic acid Chemical group OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H]1O AEMOLEFTQBMNLQ-VANFPWTGSA-N 0.000 claims abstract description 14
- 239000000375 suspending agent Substances 0.000 claims description 7
- 229920000615 alginic acid Polymers 0.000 abstract description 67
- 235000010443 alginic acid Nutrition 0.000 abstract description 66
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 abstract description 37
- 229940072056 alginate Drugs 0.000 abstract description 36
- 230000002496 gastric effect Effects 0.000 abstract description 15
- 239000011253 protective coating Substances 0.000 abstract description 11
- 229960001126 alginic acid Drugs 0.000 abstract description 7
- 239000000783 alginic acid Substances 0.000 abstract description 7
- 150000004781 alginic acids Chemical class 0.000 abstract description 7
- 239000003937 drug carrier Substances 0.000 abstract description 3
- 210000004400 mucous membrane Anatomy 0.000 abstract description 3
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 15
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 12
- 210000004877 mucosa Anatomy 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- 238000000576 coating method Methods 0.000 description 11
- 210000003238 esophagus Anatomy 0.000 description 11
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 10
- 239000011248 coating agent Substances 0.000 description 10
- 210000002784 stomach Anatomy 0.000 description 9
- 235000017557 sodium bicarbonate Nutrition 0.000 description 8
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 8
- 241000283690 Bos taurus Species 0.000 description 7
- 239000004480 active ingredient Substances 0.000 description 7
- 239000004615 ingredient Substances 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 238000013268 sustained release Methods 0.000 description 7
- 239000012730 sustained-release form Substances 0.000 description 7
- 239000001569 carbon dioxide Substances 0.000 description 6
- 229910002092 carbon dioxide Inorganic materials 0.000 description 6
- 239000006260 foam Substances 0.000 description 6
- 210000003097 mucus Anatomy 0.000 description 6
- LWIHDJKSTIGBAC-UHFFFAOYSA-K potassium phosphate Substances [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 6
- 229910000019 calcium carbonate Inorganic materials 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 206010067171 Regurgitation Diseases 0.000 description 4
- 201000006549 dyspepsia Diseases 0.000 description 4
- 210000001156 gastric mucosa Anatomy 0.000 description 4
- 229910021645 metal ion Inorganic materials 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000011736 potassium bicarbonate Substances 0.000 description 4
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 4
- 235000015497 potassium bicarbonate Nutrition 0.000 description 4
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- AEMOLEFTQBMNLQ-BZINKQHNSA-N D-Guluronic Acid Chemical compound OC1O[C@H](C(O)=O)[C@H](O)[C@@H](O)[C@H]1O AEMOLEFTQBMNLQ-BZINKQHNSA-N 0.000 description 3
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 3
- 208000007882 Gastritis Diseases 0.000 description 3
- 208000008469 Peptic Ulcer Diseases 0.000 description 3
- AEMOLEFTQBMNLQ-UHFFFAOYSA-N beta-D-galactopyranuronic acid Natural products OC1OC(C(O)=O)C(O)C(O)C1O AEMOLEFTQBMNLQ-UHFFFAOYSA-N 0.000 description 3
- 239000000227 bioadhesive Substances 0.000 description 3
- 229920001222 biopolymer Polymers 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 3
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 3
- 235000019797 dipotassium phosphate Nutrition 0.000 description 3
- 208000021302 gastroesophageal reflux disease Diseases 0.000 description 3
- 210000003736 gastrointestinal content Anatomy 0.000 description 3
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 3
- 235000019796 monopotassium phosphate Nutrition 0.000 description 3
- 230000003232 mucoadhesive effect Effects 0.000 description 3
- 229920000058 polyacrylate Polymers 0.000 description 3
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 3
- 230000002459 sustained effect Effects 0.000 description 3
- 230000008719 thickening Effects 0.000 description 3
- QFOHBWFCKVYLES-UHFFFAOYSA-N Butylparaben Chemical compound CCCCOC(=O)C1=CC=C(O)C=C1 QFOHBWFCKVYLES-UHFFFAOYSA-N 0.000 description 2
- BQENDLAVTKRQMS-SBBGFIFASA-L Carbenoxolone sodium Chemical compound [Na+].[Na+].C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C([O-])=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](OC(=O)CCC([O-])=O)C1(C)C BQENDLAVTKRQMS-SBBGFIFASA-L 0.000 description 2
- 241000195493 Cryptophyta Species 0.000 description 2
- 241001392689 Ecklonia maxima Species 0.000 description 2
- 229940122957 Histamine H2 receptor antagonist Drugs 0.000 description 2
- 241001598113 Laminaria digitata Species 0.000 description 2
- 241000296380 Laminaria hyperborea Species 0.000 description 2
- 241001491705 Macrocystis pyrifera Species 0.000 description 2
- 206010030216 Oesophagitis Diseases 0.000 description 2
- 241000199919 Phaeophyceae Species 0.000 description 2
- WINXNKPZLFISPD-UHFFFAOYSA-M Saccharin sodium Chemical compound [Na+].C1=CC=C2C(=O)[N-]S(=O)(=O)C2=C1 WINXNKPZLFISPD-UHFFFAOYSA-M 0.000 description 2
- 241000015177 Saccharina japonica Species 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 229940069428 antacid Drugs 0.000 description 2
- 239000003159 antacid agent Substances 0.000 description 2
- 239000004599 antimicrobial Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229960000530 carbenoxolone Drugs 0.000 description 2
- 239000000812 cholinergic antagonist Substances 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 210000004211 gastric acid Anatomy 0.000 description 2
- 229920001519 homopolymer Polymers 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 239000012669 liquid formulation Substances 0.000 description 2
- 239000003589 local anesthetic agent Substances 0.000 description 2
- 229960005015 local anesthetics Drugs 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 208000011906 peptic ulcer disease Diseases 0.000 description 2
- 229940126409 proton pump inhibitor Drugs 0.000 description 2
- 239000000612 proton pump inhibitor Substances 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 229960001407 sodium bicarbonate Drugs 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 229960004291 sucralfate Drugs 0.000 description 2
- MNQYNQBOVCBZIQ-JQOFMKNESA-A sucralfate Chemical compound O[Al](O)OS(=O)(=O)O[C@@H]1[C@@H](OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](COS(=O)(=O)O[Al](O)O)O[C@H]1O[C@@]1(COS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)O1 MNQYNQBOVCBZIQ-JQOFMKNESA-A 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- VQJMAIZOEPPELO-KYGIZGOZSA-N (1S,2S,6R,14R,15R,16R)-5-(cyclopropylmethyl)-16-(2-hydroxy-5-methylhexan-2-yl)-15-methoxy-13-oxa-5-azahexacyclo[13.2.2.12,8.01,6.02,14.012,20]icosa-8(20),9,11-trien-11-ol hydrochloride Chemical compound Cl.CO[C@]12CC[C@@]3(C[C@@H]1C(C)(O)CCC(C)C)[C@H]1Cc4ccc(O)c5O[C@@H]2[C@]3(CCN1CC1CC1)c45 VQJMAIZOEPPELO-KYGIZGOZSA-N 0.000 description 1
- WLAMNBDJUVNPJU-UHFFFAOYSA-N 2-methylbutyric acid Chemical compound CCC(C)C(O)=O WLAMNBDJUVNPJU-UHFFFAOYSA-N 0.000 description 1
- 241000512259 Ascophyllum nodosum Species 0.000 description 1
- 241000589151 Azotobacter Species 0.000 description 1
- 241000589149 Azotobacter vinelandii Species 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 239000004971 Cross linker Substances 0.000 description 1
- 208000012895 Gastric disease Diseases 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- IAJILQKETJEXLJ-SQOUGZDYSA-N L-guluronic acid Chemical group O=C[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O IAJILQKETJEXLJ-SQOUGZDYSA-N 0.000 description 1
- 241001466453 Laminaria Species 0.000 description 1
- 241001512709 Lessonia <stramenopiles> Species 0.000 description 1
- 241001260563 Lessonia nigrescens Species 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 229920000148 Polycarbophil calcium Polymers 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- LCWAOCHOPBSGMU-UHFFFAOYSA-J aluminum;magnesium;sodium;hydrogen carbonate;oxygen(2-);silicon;trihydroxide Chemical compound [OH-].[OH-].[OH-].[O-2].[Na+].[Mg+2].[Al+3].[Si].OC([O-])=O LCWAOCHOPBSGMU-UHFFFAOYSA-J 0.000 description 1
- 230000001078 anti-cholinergic effect Effects 0.000 description 1
- 229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 230000035587 bioadhesion Effects 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- DCSUBABJRXZOMT-IRLDBZIGSA-N cisapride Chemical compound C([C@@H]([C@@H](CC1)NC(=O)C=2C(=CC(N)=C(Cl)C=2)OC)OC)N1CCCOC1=CC=C(F)C=C1 DCSUBABJRXZOMT-IRLDBZIGSA-N 0.000 description 1
- 229960005132 cisapride Drugs 0.000 description 1
- DCSUBABJRXZOMT-UHFFFAOYSA-N cisapride Natural products C1CC(NC(=O)C=2C(=CC(N)=C(Cl)C=2)OC)C(OC)CN1CCCOC1=CC=C(F)C=C1 DCSUBABJRXZOMT-UHFFFAOYSA-N 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000005056 compaction Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- AEMOLEFTQBMNLQ-YBSDWZGDSA-N d-mannuronic acid Chemical compound O[C@@H]1O[C@@H](C(O)=O)[C@H](O)[C@@H](O)[C@H]1O AEMOLEFTQBMNLQ-YBSDWZGDSA-N 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- GXGAKHNRMVGRPK-UHFFFAOYSA-N dimagnesium;dioxido-bis[[oxido(oxo)silyl]oxy]silane Chemical compound [Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O GXGAKHNRMVGRPK-UHFFFAOYSA-N 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 208000006881 esophagitis Diseases 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229920002457 flexible plastic Polymers 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229940045140 gaviscon Drugs 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 208000024798 heartburn Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000012263 liquid product Substances 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000014380 magnesium carbonate Nutrition 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 235000012254 magnesium hydroxide Nutrition 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 229940099273 magnesium trisilicate Drugs 0.000 description 1
- 229910000386 magnesium trisilicate Inorganic materials 0.000 description 1
- 235000019793 magnesium trisilicate Nutrition 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 229950005134 polycarbophil Drugs 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002325 prokinetic agent Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 229940001593 sodium carbonate Drugs 0.000 description 1
- 235000017550 sodium carbonate Nutrition 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 241001478887 unidentified soil bacteria Species 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/734—Alginic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/10—Carbonates; Bicarbonates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nutrition Science (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Physiology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
- Materials For Medical Uses (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9708773.8A GB9708773D0 (en) | 1997-04-30 | 1997-04-30 | Organic compositions |
| GBGB9708772.0A GB9708772D0 (en) | 1997-04-30 | 1997-04-30 | Organic compositions |
| PCT/GB1998/001188 WO1998048814A1 (en) | 1997-04-30 | 1998-04-23 | Pourable alginate compositions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| PL336724A1 PL336724A1 (en) | 2000-07-03 |
| PL195031B1 true PL195031B1 (pl) | 2007-08-31 |
Family
ID=26311463
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL98336724A PL195031B1 (pl) | 1997-04-30 | 1998-04-23 | Ciekła wodna kompozycja nadająca się do nalewaniazawierająca alginian i wodorowęglan metalu alkalicznego |
| PL98378778A PL195410B1 (pl) | 1997-04-30 | 1998-04-23 | Zastosowanie kompozycji farmaceutycznej zawierającej alginian sodu do wytwarzania leku |
| PL98378779A PL194696B1 (pl) | 1997-04-30 | 1998-04-23 | Kompozycja w stałej postaci dawkowania zawierająca alginiany |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL98378778A PL195410B1 (pl) | 1997-04-30 | 1998-04-23 | Zastosowanie kompozycji farmaceutycznej zawierającej alginian sodu do wytwarzania leku |
| PL98378779A PL194696B1 (pl) | 1997-04-30 | 1998-04-23 | Kompozycja w stałej postaci dawkowania zawierająca alginiany |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US6395307B1 (https=) |
| EP (2) | EP0979091A1 (https=) |
| JP (1) | JP2001522368A (https=) |
| KR (1) | KR20010020438A (https=) |
| CN (2) | CN1197584C (https=) |
| AR (1) | AR012621A1 (https=) |
| AU (1) | AU740972B2 (https=) |
| BR (1) | BR9809310A (https=) |
| CA (1) | CA2288743C (https=) |
| ID (1) | ID23809A (https=) |
| PL (3) | PL195031B1 (https=) |
| WO (1) | WO1998048814A1 (https=) |
| ZA (1) | ZA983707B (https=) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0005743D0 (en) | 2000-03-10 | 2000-05-03 | Reckitt & Colmann Prod Ltd | Pharmaceutical compositions including alginates |
| IL149030A0 (en) * | 2000-08-09 | 2002-11-10 | Panacea Biotec Ltd | Pharmaceutical compositions containing rifampicin, isoniazid or combinations thereof |
| GB0107651D0 (en) * | 2001-03-27 | 2001-05-16 | Syngenta Ltd | Composition |
| WO2003024316A2 (en) * | 2001-09-21 | 2003-03-27 | Stryker Corporation | Pore-forming agents for orthopedic cements |
| GB2384986B (en) * | 2002-02-12 | 2004-01-07 | Reckitt Benckiser Healthcare | Compositions for the treatment of disorders of the upper gastrointestinal tract |
| US7135027B2 (en) * | 2002-10-04 | 2006-11-14 | Baxter International, Inc. | Devices and methods for mixing and extruding medically useful compositions |
| JP4873877B2 (ja) * | 2005-03-30 | 2012-02-08 | 小林製薬株式会社 | アルギン酸ナトリウム含有錠剤の製造方法及び該製造方法により得られる錠剤 |
| HUE034051T2 (en) | 2007-11-27 | 2018-01-29 | Algipharma As | Use of alginate-containing oligomers to combat biofilms |
| WO2010092468A1 (en) * | 2009-02-13 | 2010-08-19 | Carlo Ghisalberti | Composition comprising alginates and d-limonene to treat gerd and dyspepsia |
| ES2444541T3 (es) | 2009-06-03 | 2014-02-25 | Algipharma As | Oligómeros de alginato para usar para superar la multirresistencia a fármacos en bacterias |
| CN101933894B (zh) * | 2009-07-03 | 2012-07-11 | 张清 | 胃肠粘膜保护胶 |
| KR20130091250A (ko) | 2010-04-23 | 2013-08-16 | 에스-바이오텍 홀딩 에이피에스 | 위산 중화용 고체 약학 조성물 |
| EA015747B1 (ru) * | 2010-07-08 | 2011-10-31 | Общество С Ограниченной Ответственностью "Вдс" | Состав для профилактики кандидозов |
| DK177435B1 (en) | 2011-06-03 | 2013-05-21 | Biotek Holding Aps S | An aqueous diet product, a unit dosage and a kit comprising at least one alginate, and a method for the preparation of said diet product |
| US9636360B2 (en) | 2012-09-18 | 2017-05-02 | pH Science Holdings, Inc | Method and composition for treating gastro-esophageal disorders |
| EP2938347A4 (en) | 2012-12-30 | 2016-08-10 | Hadasit Med Res Service | USE OF ALGINATE COMPOSITIONS TO PREVENT OR PREVENT LIVER DAMAGE THROUGH HEPATOTOXIC |
| US11931227B2 (en) | 2013-03-15 | 2024-03-19 | Cook Medical Technologies Llc | Bimodal treatment methods and compositions for gastrointestinal lesions with active bleeding |
| ITUB20150279A1 (it) * | 2015-03-09 | 2016-09-09 | S I I T S R L Servizio Int Imballaggi Termosaldanti | Sistema flottante per la cura dei sintomi delle affezioni gastriche |
| US11452798B2 (en) | 2017-09-27 | 2022-09-27 | Cook Medical Technologies Llc | Crosslinking submucosal injectate system |
| WO2019092608A1 (en) * | 2017-11-08 | 2019-05-16 | Materias S.R.L. | In situ gelifying powder |
| CN108451973A (zh) * | 2018-01-30 | 2018-08-28 | 无锡福尔顺科技有限公司 | 一种消化道凝胶保护剂及其使用方法和应用 |
| IT202100000059A1 (it) * | 2021-01-04 | 2022-07-04 | Nyuma Pharma Srl | Nuove composizioni di sucralfato in alginato e loro utilizzo in terapia |
| WO2023018649A1 (en) * | 2021-08-10 | 2023-02-16 | Bayer Healthcare Llc | Liquid formulations comprising alginic acid, pectin, and carrageenan and methods of using thereof for gastric and gastroesophageal disorders |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1524740A (en) * | 1976-11-09 | 1978-09-13 | Reckitt & Colmann Prod Ltd | Pharmaceutical compositions for use in the suppression of gastric reflux |
| GB1566609A (en) * | 1977-03-10 | 1980-05-08 | Reckitt & Colmann Prod Ltd | Pharmaceutical compositions containing cholestyramine and alginic acid |
| JPS5746920A (en) | 1980-09-03 | 1982-03-17 | Kyosei Seiyaku Kk | Drug for digestive tract |
| DE3152319C2 (de) * | 1980-09-03 | 1986-05-07 | Kyosei Pharmaceutical Co., Ltd., Hokkaido | Verwendung einer Lösung eines Salzes der Alginsäure zur Behandlung von Strahlenschäden und Ulcera |
| JPH0764737B2 (ja) * | 1984-04-19 | 1995-07-12 | ローヌ−プーラン ローラー インターナショナル （ホウルディングス） インコーポレイテッド | 制酸組成物 |
| US4869902A (en) * | 1984-04-19 | 1989-09-26 | Rorer Pharmaceutical Corporation | Antacid composition |
| US4744986A (en) * | 1986-03-07 | 1988-05-17 | Rorer Pharmaceutical Corporation | Process for the preparation of a viscosity-stable antacid composition |
| GB8618847D0 (en) * | 1986-08-01 | 1986-09-10 | Smith Kline French Lab | Pharmaceutical formulations |
| DK179687D0 (da) * | 1987-04-08 | 1987-04-08 | Farma Food As | Praeparat |
| GB9010039D0 (en) * | 1990-05-03 | 1990-06-27 | Reckitt & Colmann Prod Ltd | Medicament preparation |
| GB9218749D0 (en) * | 1992-09-04 | 1992-10-21 | Courtaulds Plc | Alginate gels |
| US5888540A (en) * | 1993-10-29 | 1999-03-30 | Sugden; Keith | Pharmaceutical products |
| GB9504599D0 (en) * | 1995-03-03 | 1995-04-26 | Reckitt & Colmann Prod Ltd | Improvements in or relating to organic compositions |
| GB2298365B (en) | 1995-03-03 | 1997-05-07 | Reckitt & Colmann Prod Ltd | A liquid pharmaceutical composition alginate and potassium bicarbonate |
-
1998
- 1998-04-23 US US09/403,217 patent/US6395307B1/en not_active Expired - Fee Related
- 1998-04-23 PL PL98336724A patent/PL195031B1/pl not_active IP Right Cessation
- 1998-04-23 CA CA002288743A patent/CA2288743C/en not_active Expired - Fee Related
- 1998-04-23 EP EP98917452A patent/EP0979091A1/en not_active Ceased
- 1998-04-23 EP EP06024990A patent/EP1842544A3/en not_active Withdrawn
- 1998-04-23 ID IDW991279A patent/ID23809A/id unknown
- 1998-04-23 CN CNB98804594XA patent/CN1197584C/zh not_active Expired - Lifetime
- 1998-04-23 CN CNB2004100461678A patent/CN1286468C/zh not_active Expired - Fee Related
- 1998-04-23 AU AU70680/98A patent/AU740972B2/en not_active Expired
- 1998-04-23 BR BR9809310-0A patent/BR9809310A/pt not_active Application Discontinuation
- 1998-04-23 PL PL98378778A patent/PL195410B1/pl not_active IP Right Cessation
- 1998-04-23 WO PCT/GB1998/001188 patent/WO1998048814A1/en not_active Ceased
- 1998-04-23 JP JP54671798A patent/JP2001522368A/ja not_active Ceased
- 1998-04-23 KR KR1019997010069A patent/KR20010020438A/ko not_active Withdrawn
- 1998-04-23 PL PL98378779A patent/PL194696B1/pl not_active IP Right Cessation
- 1998-04-28 ZA ZA983707A patent/ZA983707B/xx unknown
- 1998-04-29 AR ARP980101993A patent/AR012621A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU7068098A (en) | 1998-11-24 |
| CN1253505A (zh) | 2000-05-17 |
| US6395307B1 (en) | 2002-05-28 |
| PL194696B1 (pl) | 2007-06-29 |
| CN1197584C (zh) | 2005-04-20 |
| EP0979091A1 (en) | 2000-02-16 |
| EP1842544A2 (en) | 2007-10-10 |
| CN1286468C (zh) | 2006-11-29 |
| KR20010020438A (ko) | 2001-03-15 |
| ZA983707B (en) | 1999-02-26 |
| ID23809A (id) | 2000-05-11 |
| CA2288743C (en) | 2008-04-22 |
| PL336724A1 (en) | 2000-07-03 |
| PL195410B1 (pl) | 2007-09-28 |
| BR9809310A (pt) | 2000-07-04 |
| WO1998048814A1 (en) | 1998-11-05 |
| AR012621A1 (es) | 2000-11-08 |
| EP1842544A3 (en) | 2007-10-17 |
| CN1552344A (zh) | 2004-12-08 |
| AU740972B2 (en) | 2001-11-15 |
| CA2288743A1 (en) | 1998-11-05 |
| JP2001522368A (ja) | 2001-11-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL195031B1 (pl) | Ciekła wodna kompozycja nadająca się do nalewaniazawierająca alginian i wodorowęglan metalu alkalicznego | |
| ES2311516T3 (es) | Uso de polifosfato como inhibidor de la erosion dental en composiciones acidas. | |
| JP2003500361A (ja) | 水和と再水和を維持するための電解質ゲル | |
| JPS646172B2 (https=) | ||
| AU696480B2 (en) | Liquid aqueous pharmaceutical compositions comprising sodium alginate and potassium bicarbonate | |
| US4315918A (en) | Pharmaceutical formulation of guar gum | |
| GB2324725A (en) | Alinate/Alginic Acid Composition | |
| US9433644B2 (en) | Formulations and methods for treating oral inflammation, injury, or pain | |
| HU219334B (en) | Antacid composition and process for its production | |
| MXPA02008842A (es) | Composiciones farmaceuticas que incluyen alginatos. | |
| US20110287062A1 (en) | Chewable Formulation Comprising Alginate, Bicarbonate And Carbonate | |
| GB2298365A (en) | A Pharmaceutical Liquid Comprising Potassium Bicarbonate and Sodium Alginate | |
| DE60204519T2 (de) | Im Ruhezustand Gefrorenes | |
| CA2614617A1 (en) | Pourable alginate compositions | |
| CZ380899A3 (cs) | Tekuté alginatové prostředky | |
| GB2324724A (en) | A Concentrated Aqueous Sodium Alginate Composition | |
| RU2173139C2 (ru) | Усовершенствования органических композиций или усовершенствования, относящиеся к этим композициям | |
| MXPA97006661A (en) | Improvements in organic or related compositionswith |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| LAPS | Decisions on the lapse of the protection rights |
Effective date: 20140423 |